BioSpace News Archive

Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week ® 2022.

Ambys Medicines today announced that new data from its novel hepatocyte cell therapy platform and universal hepatocyte program will be highlighted in three presentations at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, which will be held on May 16-19, 2022, in Washington, D.C.

BIOLASE, Inc., the global leader in dental lasers, announced that Kenneth P. Yale, D.D.S., J.D. was newly elected to its Board of Directors, effective April 28, 2022.

Cano Health, Inc. today announced financial results for the first quarter ended March 31, 2022 .

Berlin-based digital health company Fosanis, the developer of Mika, Germany’s first prescription DTx for all oncological indications, closed a series A funding round of more than 10 million EUR.

Ra Medical Systems, Inc . (NYSE American: RMED) announces that it will report financial results for the three months ended March 31, 2022 after market close on Monday, May 16.

NovaBay ® Pharmaceuticals, Inc . announces the expansion of its top-selling Kakadu C and Calm Cool + Corrected product lines with the introduction of next-generation products that are uniquely formulated with anti-aging ingredients to help reduce the appearance of wrinkles, fine lines, pores and discoloration.

ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the presentation of clinical data from the PRIMROSE (1 and 2) Phase 3 studies of linzagolix for the treatment of heavy menstrual bleeding associated with uterine fibroids at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM).

MoonLake Immunotherapeutics AG (Nasdaq: MLTX) (MoonLake, or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that the British Journal of Dermatology (BJD) has published a new data analysis, which can be accessed in the BJD online library, from the Phase 2b clinical trial assessing the effect of sonelokimab on moderate to severe plaque type psoriasis over 48 weeks (NCT03384745).

Trevena, Inc. announced that it will release its financial results for the first quarter ended March 31, 2022, prior to the market open on Wednesday, May 11, 2022.